NRXS

SEC source: 0001493152-26-046382 · ownership.xml · nonDerivative · entry 1

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,604

SEC source: 0001493152-26-046381 · ownership.xml · nonDerivative · entry 1

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,673

SEC source: 0001493152-26-046380 · ownership.xml · nonDerivative · entry 1

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,530

SEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 4

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 3

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,000

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040274 · ownership.xml · derivative · entry 2

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 320,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040274 · ownership.xml · nonDerivative · entry 1

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,336

F1 · shares: Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

F1 · price: Reference is made to the 320,000 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 120,812 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

SEC source: 0001493152-26-040275 · ownership.xml · derivative · entry 4

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040275 · ownership.xml · derivative · entry 3

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 306,236

Underlying: Common Stock · Not disclosed shares

Expires not disclosed

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.underlying_shares: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040275 · ownership.xml · derivative · entry 2

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 306,236 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040275 · ownership.xml · nonDerivative · entry 1

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,345

F1 · shares: Reference is made to the 306,236 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 112,558 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

F1 · price: Reference is made to the 306,236 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 112,558 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

SEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 4

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 337,204 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 3

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,204

Underlying: Common Stock · 337,204 shares

Expires not disclosed

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 2

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 337,204 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.

SEC source: 0001493152-26-040276 · ownership.xml · nonDerivative · entry 1

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,106

F1 · shares: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

F1 · price: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.

SEC source: 0001493152-26-038824 · ownership.xml · derivative · entry 1

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,479

Underlying: Common Stock · 141,479 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-038827 · ownership.xml · nonDerivative · entry 1

Keyser Jane Elizabeth · CIK 0001959756 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,408

F1 · shares: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-038817 · ownership.xml · derivative · entry 1

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,329

Underlying: Common Stock · 193,329 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-038821 · ownership.xml · nonDerivative · entry 1

Ferge Kristin A · CIK 0001343345 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,072

F1 · shares: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-038815 · ownership.xml · nonDerivative · entry 2

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,058

F2 · shares: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

F2 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-038831 · ownership.xml · nonDerivative · entry 1

Watkins Bradley Mitchell · CIK 0001959534 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,408

F1 · shares: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-038829 · ownership.xml · derivative · entry 1

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,341

Underlying: Common Stock · 133,341 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-038819 · ownership.xml · derivative · entry 1

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,906

Underlying: Common Stock · 135,906 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-038815 · ownership.xml · nonDerivative · entry 3

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Rosalind Advisors, Inc., the advisor to the Rosalind Master Fund L.P.

Disclosed balance after: 548,123

F1 · shares: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

F1 · price: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

F3 · ownership.nature: Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001493152-26-038815 · ownership.xml · nonDerivative · entry 1

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,128

F1 · shares: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

F1 · price: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

SEC source: 0001493152-26-020778 · ownership.xml · nonDerivative · entry 2

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Rosalind Advisors, Inc., the advisor to the Rosalind Master Fund L.P.

Disclosed balance after: 508,055

F3 · price: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

F2 · balance_after: Includes (1) 286,138 shares of common stock purchased by Rosalind Master Fund L.P. in which the Reporting Person has indirect ownership as previously disclosed, and (2) 221,917 shares of common stock issued as a dividend on the Series B Preferred Stock owned by Rosalind Master Fund L.P.

F4 · ownership.nature: Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001493152-26-020778 · ownership.xml · nonDerivative · entry 1

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,902

F3 · price: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 221,917 and 12,304, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.

F1 · balance_after: Includes (1) 21,598 shares of common stock issued to the Reporting Person as previously disclosed, and (2) 12,304 shares of common stock issued to the Reporting Person as a dividend on the Series B Preferred Stock owned by the Reporting Person.

SEC source: 0001493152-26-015073 · ownership.xml · nonDerivative · entry 1

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,593

SEC source: 0001493152-26-015069 · ownership.xml · nonDerivative · entry 1

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 348,178

SEC source: 0001493152-26-015071 · ownership.xml · nonDerivative · entry 1

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,903

SEC source: 0001437749-26-004101 · rdgdoc.xml · nonDerivative · entry 2

Hannasch Brian · CIK 0001911504 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,211,522

F2 · price: Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 12, 2026 with purchase prices ranging from $4.70 to $4.95 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001437749-26-004101 · rdgdoc.xml · nonDerivative · entry 1

Hannasch Brian · CIK 0001911504 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,171,522

F1 · price: Reflects the weighted average price of 40,000 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on February 11, 2026 with purchase prices ranging from $4.53 to $4.85 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001493152-26-004588 · ownership.xml · nonDerivative · entry 1

Ferge Kristin A · CIK 0001343345 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,938

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-004590 · ownership.xml · nonDerivative · entry 1

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,736

F2 · price: 21,598 shares of common stock were issued to the Reporting Person as compensation for services as independent director of the Issuer.

F1 · balance_after: Includes (1) 286,138 shares of common stock owned by Rosalind Master Fund L.P., and (2) 21,598 shares of common stock issued to the Reporting Person as compensation for services as an independent director of the Issuer.

SEC source: 0001493152-26-008234 · ownership.xml · nonDerivative · entry 1

Keyser Jane Elizabeth · CIK 0001959756 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,335

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-008233 · ownership.xml · derivative · entry 1

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,231

Underlying: Common Stock · 75,231 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-008231 · ownership.xml · derivative · entry 1

Carrico Brian Allen · CIK 0001959279 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,173

Underlying: Common Stock · 94,173 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-008235 · ownership.xml · nonDerivative · entry 1

Watkins Bradley Mitchell · CIK 0001959534 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,335

F1 · price: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

SEC source: 0001493152-26-008232 · ownership.xml · derivative · entry 1

Carrico Thomas Joeseph · CIK 0001959325 · CRO, CCO, CPO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,569

Underlying: Common Stock · 47,569 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001493152-26-008545 · ownership.xml · derivative · entry 1

Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,569

Underlying: Common Stock · 47,569 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

SEC source: 0001811824-25-000002 · primary_doc.xml · nonDerivative · entry 1

Aharon Gil · CIK 0001811824 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Rosalind Advisors, Inc., the advisor to the Rosalind Master Fund L.P.

Disclosed balance after: 286,138

F1 · shares: Rosalind Master Fund L.P. purchased 286,138 common shares at $3.52

F2 · ownership.nature: Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.

SEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · derivative · entry 4

MASIMO CORP · CIK 0000937556 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 289,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock.

F1 · derivative.expiration_date: The Pre-Funded Warrant (the "Warrant") is currently exercisable and has no expiration date. Upon the Issuer's consummation of an initial public offering, the Warrant automatically converted into a warrant exercisable for 289,779 shares of Issuer's Common Stock, and the exercise price was adjusted to be $0.0005 per share of the Issuer's Common Stock.

SEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 3

MASIMO CORP · CIK 0000937556 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 2

MASIMO CORP · CIK 0000937556 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000937556-25-000098 · wk-form4_1751578681.xml · nonDerivative · entry 1

MASIMO CORP · CIK 0000937556 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001437749-25-022096 · rdgdoc.xml · nonDerivative · entry 1

Hannasch Brian · CIK 0001911504 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,131,522

SEC source: 0001437749-25-012821 · rdgdoc.xml · nonDerivative · entry 1

Hannasch Brian · CIK 0001911504 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 775,966

F1 · price: Reflects the weighted average price of 18,065 shares of common stock of Neuraxis, Inc. purchased by the reporting person in multiple transactions on April 21, 2025 with purchase prices ranging from $1.60 to $1.80 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001641172-25-027020 · ownership.xml · derivative · entry 2

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F2 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person as the hiring grant. The RSUs will vest in full at the end of 36 months

F2 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person as the hiring grant. The RSUs will vest in full at the end of 36 months

F2 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person as the hiring grant. The RSUs will vest in full at the end of 36 months

SEC source: 0001641172-25-027020 · ownership.xml · derivative · entry 1

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,037

Underlying: Common Stock · 8,037 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation for services as independent director of the Issuer. The RSUs will vest in full at the end of 36 months.

F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation for services as independent director of the Issuer. The RSUs will vest in full at the end of 36 months.

F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation for services as independent director of the Issuer. The RSUs will vest in full at the end of 36 months.

SEC source: 0001641172-25-027020 · ownership.xml · derivative · entry 3

Henrichs Timothy Robert · CIK 0001959954 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,000

Underlying: Common Stock · 66,000 shares

Expires not disclosed

F3 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

F3 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.

F3 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months.